

HEDIS® Tips:

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

MEASURE DESCRIPTION

The percentage of children or adolescents 1-17 years of age who had at least two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported:

1. The percentage of children and adolescents on antipsychotics who received blood glucose testing.
2. The percentage of children and adolescents on antipsychotics who received cholesterol testing.
3. The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.

CODES INCLUDED IN THE CURRENT HEDIS® MEASURE

Codes to Identify	Description	Code
Diabetes Screening	Glucose Tests	CPT®: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
Diabetes Screening	HbA1c Test & Lab Results	CPT®: 83036, 83037 CPT®II: 3044F (<7%), 3046F (>9%), 3051F (≥7% and <8%), 3052F (≥8% and <9%)
Cholesterol Screening	Cholesterol Tests	CPT®: 82465, 83718, 83722, 84478
Cholesterol Screening	LDL-C Test & Lab Results	CPT®: 83036, 83037 CPT®II: 3048F (<100 mg/dL), 3049F (100-129 mg/dL), 3050 (≥130 mg/dL)

MEDICATIONS

Medication Type	Description	Prescription
Antipsychotic	Miscellaneous Antipsychotic Agents	Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Molindone, Olanzapine, Paliperodine, Pimozide, Quetiapine, Risperidone, Ziprasidone
Antipsychotic	Phenothiazine Antipsychotics	Chlorpromazine, Fluphenazine, Perphenazine, Thioridazine, Trifluoperazine
Antipsychotic	Thioxanthenes	Thiothixene
Antipsychotic	Long-acting Injections	Aripiprazole, Aripiprazole lauroxil, Fluphenazine decanoate, Haloperidol decanoate, Olanzapine, Perphenazine palmitate, Risperidone
Antipsychotic Combination	Psychotherapeutic Combinations*	Fluoxetine-olanzapine, Perphenazine-amitriptyline
Prochlorperazine	Phenothiazine Antipsychotics	Prochlorperazine

***Please submit a request for coverage when prescribing Psychotherapeutic Combination medications.**

HOW TO IMPROVE HEDIS® SCORES

- Monitoring children on antipsychotic medications helps to avoid metabolic health complications such as weight gain and diabetes.
- Educate parents/guardians about the signs of metabolic disturbances, including long term consequences of pediatric and adolescence obesity and poor cardiometabolic outcomes in adulthood.
- Establish a baseline and continuously monitor metabolic indices to ensure appropriate management of side-effects of antipsychotic medication therapy.
- Explore partnering with key community and school-based organizations focused on child/adolescent health to provide education about healthy diet, nutrition and exercise.
- Consider prescribing long-acting injectable medications for non-compliance issues.
- Schedule follow-up appointments after the second anti-psychotic prescription and metabolic lab tests.

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA. The NCQA HEDIS measure specification has been adjusted pursuant to NCQA's *Rules for Allowable Adjustments of HEDIS*. The adjusted measure specification may be used only for internal quality improvement purposes.

Updated 02/21/2022

All summaries of the measures contained herein are reproduced with permission from HEDIS® Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Molina Healthcare, Inc. does not warrant or represent that the information contained herein is accurate or free from defects.

COPYRIGHT NOTICE AND DISCLAIMER

The HEDIS® measures and specifications were developed by and are owned by NCQA. The HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures and specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the *Rules for Allowable Adjustments of HEDIS* to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program.

Reprinted with permission by NCQA. ©2021 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measure specifications.

The American Hospital Association holds a copyright to the Uniform Billing Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. The UB Codes contained in the HEDIS specifications may be used by health plans and other health care delivery organizations for the purpose of calculating and reporting HEDIS measure results or using HEDIS measure results for their internal quality improvement purposes. All other uses of the UB Codes require a license from the AHA. Anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.